| Literature DB >> 22514337 |
Stephanie A Freel1, Ralph A Picking, Guido Ferrari, Haitao Ding, Christina Ochsenbauer, John C Kappes, Jennifer L Kirchherr, Kelly A Soderberg, Kent J Weinhold, Coleen K Cunningham, Thomas N Denny, John A Crump, Myron S Cohen, Andrew J McMichael, Barton F Haynes, Georgia D Tomaras.
Abstract
CD8-mediated virus inhibition can be detected in HIV-1-positive subjects who naturally control virus replication. Characterizing the inhibitory function of CD8(+) T cells during acute HIV-1 infection (AHI) can elucidate the nature of the CD8(+) responses that can be rapidly elicited and that contribute to virus control. We examined the timing and HIV-1 antigen specificity of antiviral CD8(+) T cells during AHI. Autologous and heterologous CD8(+) T cell antiviral functions were assessed longitudinally during AHI in five donors from the CHAVI 001 cohort using a CD8(+) T cell-mediated virus inhibition assay (CD8 VIA) and transmitted/founder (T/F) viruses. Potent CD8(+) antiviral responses against heterologous T/F viruses appeared during AHI at the first time point sampled in each of the 5 donors (Fiebig stages 1/2 to 5). Inhibition of an autologous T/F virus was durable to 48 weeks; however, inhibition of heterologous responses declined concurrent with the resolution of viremia. HIV-1 viruses from 6 months postinfection were more resistant to CD8(+)-mediated virus inhibition than cognate T/F viruses, demonstrating that the virus escapes early from CD8(+) T cell-mediated inhibition of virus replication. CD8(+) T cell antigen-specific subsets mediated inhibition of T/F virus replication via soluble components, and these soluble responses were stimulated by peptide pools that include epitopes that were shown to drive HIV-1 escape during AHI. These data provide insights into the mechanisms of CD8-mediated virus inhibition and suggest that functional analyses will be important for determining whether similar antigen-specific virus inhibition can be induced by T cell-directed vaccine strategies.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22514337 PMCID: PMC3393529 DOI: 10.1128/JVI.00437-12
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103